Virtual Library
Start Your Search
Jin-Shing Chen
Author of
-
+
OA03 - Advances in Lung Cancer Pathology (ID 897)
- Event: WCLC 2018
- Type: Oral Abstract Session
- Track: Pathology
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 10:30 - 12:00, Room 205 BD
-
+
OA03.06 - Extraction of Radiomic Values from Lung Adenocarcinoma with Near-Pure Histological Subtypes (ID 13840)
11:25 - 11:35 | Author(s): Jin-Shing Chen
- Abstract
- Presentation
Background
Histological subtypes of lung adenocarcinomas classified by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) system have been investigated using radiomic approaches. However, the results have had limitations since of invasive lung adenocarcinomas may be heterogeneous, with two or more subtypes. To reduce the influence of heterogeneity during radiomic analysis, computed tomography (CT) images of lung adenocarcinomas with near-pure adenocarcinoma subtypes were analyzed to extract representative radiomic features of different subtypes.
a9ded1e5ce5d75814730bb4caaf49419 Method
We enrolled 95 patients who underwent complete resection for lung adenocarcinoma and a pathological diagnosis of a “near-pure” (≥70%) IASLC/ATS/ERS histological subtype. Conventional histogram/morphological features and complex radiomic features (grey-level-based statistical features and component variance-based features) of thin-cut CT data of tumor regions were analyzed. A prediction model based on leave-one-out cross-validation (LOOCV) and logistic regression (LR) was used to classify all five subtypes and three pathologic grades (lepidic, acinar/papillary, micropapillary/solid) of adenocarcinomas. The validation was performed using 36 near-pure adenocarcinomas in a later cohort.
4c3880bb027f159e801041b1021e88e8 Result
A total of 31 lepidic, 14 papillary, 32 acinar, 10 micropapillary, and 8 solid adenocarcinomas were analyzed. With 21 conventional and complex radiomic features, for 5 subtypes and 3 pathological grades, the prediction models achieved accuracy rates of 84.2% (80/95) and 91.6% (87/95), respectively, while accuracy was 71.6% and 85.3%, respectively, if only conventional features were used. The accuracy rate for the validation set (n=36) was 83.3% (30/36) and 94.4% (34/36) in 5 subtypes and 3 pathological grades, respectively, using conventional and complex features, while it was 66.7% and 77.8% only using conventional features, respectively.
8eea62084ca7e541d918e823422bd82e Conclusion
Lung adenocarcinoma with high purity histological subtypes demonstrates strong stratification of radiomic values, which provide basic information for accurate pathological subtyping and image parcellation of tumor sub-regions.
6f8b794f3246b0c1e1780bb4d4d5dc53
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.01-36 - Thoracic Surgery in Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy (ID 11170)
16:45 - 18:00 | Author(s): Jin-Shing Chen
- Abstract
Background
Advanced stage non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor (EGFR) mutation have benefit form treatment with tyrosine kinase inhibitors (TKI). However, the role of multidisciplinary management including neoadjuvant TKI therapy and thoracic surgery is uncertain in advanced stage NSCLC. This retrospective study assessed the impact of the multidisciplinary management in advanced stage EGFR mutation positive NSCLC patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
Advanced stage NSCLC patients were retrospectively identified at Department of Surgery, National Taiwan University Hospital from 2006 to 2013 and prospectively observed. Patients with stage IIIA N2 (unresectable), IIIB, and IV EGFR mutation positive NSCLC treated with neoadjuvant TKI without tumor progression followed by thoracic surgery (NT group) were evaluated. Patients with stage IIIA N2 NSCLC treated with cisplatin-based neoadjuvant chemotherapy without tumor progression followed by thoracic surgery (NC group) were also evaluated. Progression-free survival (PFS) and overall survival (OS) were analyzed.
4c3880bb027f159e801041b1021e88e8 Result
There were total 88 NSCLC patients in this study. There were 41 men and 47 women. The median age was 58 years. 66 patients were the NC group and 22 patients were the NT group. 60 patients and 20 patients were adenocarcinoma in the NC group and the NT group, respectively. Other patients were squamous cell carcinoma. In the NT group, EGFR status was identified before receiving neoadjuvant TKI therapy. Twelve patients (54.5%) were exon 19 deletion and ten patients were exon 21 L858R mutation. PFS was not significantly different between NC group and NT group (p = 0.645). OS was significantly longer in the NT group than in the NC group (p = 0.028). Exon 19 deletion of the NT group patients had significantly longer OS than the NC group (p = 0.014).
8eea62084ca7e541d918e823422bd82e Conclusion
The multidisciplinary management including neoadjuvant TKI therapy and thoracic surgery may possibly have benefit in selected advanced stage NSCLC patients haboring exon 19 deletion.
6f8b794f3246b0c1e1780bb4d4d5dc53
